Skip to main content
. 2022 Aug 3;12:960340. doi: 10.3389/fonc.2022.960340

Figure 8.

Figure 8

Future outlook of in vitro H&N cancer patient-derived organoid (PDO) models. (A) Sourcing of H&N PDO models using the tumor biopsies of cancer patients and CRISPR DNA–modified healthy cells. (B) Fabrication of H&N PDO models using bioprinting. (C) H&N PDO model life span used as air–liquid interface in HTS for personalized medicine purposes. Figure created with BioRender.com.